Patents by Inventor Albert C. Gyorkos

Albert C. Gyorkos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9422298
    Abstract: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3? OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: August 23, 2016
    Assignees: CMG Pharmaceutical Co., Ltd., Sung Kwang Medical Foundation
    Inventors: Gilnam Lee, Chul Soo Lim, Han Won Cho, Jeongbeob Seo, Albert C. Gyorkos, Suk Young Cho, Eun Kyung Choi, Choung Soo Kim, Jung Jin Hwang, Jin Sung Kim, Hee Jung An, Yong Wha Moon
  • Publication number: 20150158874
    Abstract: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3? OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 11, 2015
    Inventors: Gilnam Lee, Chul Soo Lim, Han Won Cho, Jeongbeob Seo, Albert C. Gyorkos, Suk Young Cho, Eun Kyung Choi, Choung Soo Kim, Jung Jin Hwang, Jin Sung Kim
  • Publication number: 20140113915
    Abstract: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3? OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 24, 2014
    Applicant: THE ASAN FOUNDATION
    Inventors: Gilnam Lee, Chul Soo Lim, Han Won Cho, Jeongbeob Seo, Albert C. Gyorkos, Suk Young Cho, Eun Kyung Choi, Choung Soo Kim, Jung Jin Hwang
  • Patent number: 6159938
    Abstract: Provided are methods of inhibiting the activity of a serine protease using protease inhibitors that include an alpha-keto heterocycle in their structure. The methods are useful in the treatment of ischemic heart or treatment of symptoms associated with blood coagulation disorders. Also provided are methods for detecting or quantifying the activity of a serine protease in a pure sample.
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: December 12, 2000
    Assignee: Cortech, Inc.
    Inventors: Albert C. Gyorkos, Lyle W. Spruce, Axel H. Leimer, John C. Cheronis
  • Patent number: 6150334
    Abstract: The present invention relates to certain compounds comprising substituted oxadiazole, thiadiazole and triazole structures which are useful as inhibitors of serine proteases, including human neutrophil elastase (HNE). Compounds described herein are characterized by their relatively low molecular weight, high potency and selectivity with respect to HNE, and can be used to effectively prevent, alleviate or otherwise treat disease states characterized by the degradation of connective tissue by proteases in humans.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: November 21, 2000
    Assignee: Cortech, Inc.
    Inventors: Albert C. Gyorkos, Lyle W. Spruce
  • Patent number: 6100238
    Abstract: The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: August 8, 2000
    Assignee: Cortech Inc.
    Inventors: Albert C. Gyorkos, Lyle W. Spruce
  • Patent number: 6004933
    Abstract: The present invention relates to cysteine protease inhibitors of the general formula (I): ##STR1## wherein Z is a cysteine protease binding moiety; X and Y are S, O or optionally substituted N; and R.sub.1 is optionally substituted alkyl or aryl.
    Type: Grant
    Filed: April 23, 1998
    Date of Patent: December 21, 1999
    Assignee: Cortech Inc.
    Inventors: Lyle W. Spruce, Albert C. Gyorkos, John C. Cheronis, Val S. Goodfellow, Axel H. Leimer, John M. Young, James Ivan Gerrity
  • Patent number: 6001814
    Abstract: The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Cortech Inc.
    Inventors: Albert C. Gyorkos, Lyle W. Spruce
  • Patent number: 6001813
    Abstract: The present invention relates to certain substituted oxadiazole tripeptides, which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Cortech Inc.
    Inventors: Albert C. Gyorkos, Lyle W. Spruce